%0 Journal Article
%T Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
%A Azar P
%A Schneiderman H
%A Barron H
%A Wong JSH
%A Meyer M
%A Newman-Azar D
%A Narimani M
%A Ignaszewski MJ
%A Mathew N
%A Mullen R
%A Krausz RM
%A Maharaj AR
%J Addict Sci Clin Pract
%V 19
%N 1
%D 2024 06 18
%M 38886826
暂无%R 10.1186/s13722-024-00479-1
%X Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier.<BR>We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms.<BR>This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.